KardiaNova is an innovative biotech company addressing the unmet global burden of cardiotoxicity in breast cancer patients.
+2.3mio new cases of breast cancer every year globally
+685k yearly deaths
by breast cancer
1/8 women get
breast cancer
1/3 women who survive breast cancer eventually die of heart disease
KardiaNova’s proprietary organoid technology is uniquely ready to provide a highly accurate & scalable platform for studying cardiotoxicity risk using human cardiac tissues containing patient-derived cells. This innovative approach offers several advantages:
KardiaNova’s goal is to achieve proof-of-concept (POC) for our organoid technology. After success in breast cancer our protected platform methodology can be applied to other common cancers such as: NSCLC, CRC, lung, melanoma, ovarian and prostatic cancers.
CEO & scientific director
of HRI (Sydney)
CBO & Board Member
at One LiiF (Brussels)
Senior Lecturer School of Biomedical Engineering (Sydney)
Chief of Cardiology, CHU Helora & Professor of Cardiology, University of Mons
Prof Andrew JS Coats, DM, DSc, MBA, AO is co-founder of PsiOxus Therapeutics, Actimed Therapeutics and BioVentrix.
© KardiaNova 2024
Privacy policy